Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 424 (LINC00424) is a long non-coding RNA (lncRNA), meaning it does not encode a protein but instead functions at the RNA level. It has been identified as highly expressed in liver cancer tissues and serum in comparison to normal controls, with elevated levels correlating with advanced tumor stage, lymph node metastasis, and poor prognosis. LINC00424 has potential diagnostic utility, as its expression in serum reflects its status in tumor tissues. However, it is not a canonical therapeutic target like a receptor, enzyme, or transporter, but rather may serve as a biomarker for patient selection or prognosis in cancer. No known drugs directly target LINC00424, and it is not established as a direct drug target in current therapeutics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 424 (LINC00424).